196p -0.5 -0.3%
Last Trade - 20/01/21
| Market Cap | £266.5m |
| Enterprise Value | £223.1m |
| Revenue | £432k |
| Position in Universe | 744th / 1804 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.001 | 0.64 | 1.86 | 1.33 | 0.51 | 0.75 | 1.00 | +374.3% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | September 15, 2015 |
| Public Since | February 17, 2017 |
| No. of Shareholders: | n/a |
| No. of Employees: | 730 |
| Sector | Financials |
| Industry | Holding Companies |
| Index | |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 135,609,653 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom |
| Web | https://arixbioscience.com/ |
| Phone | +44 20 72901050 |
| Contact | Charlotte Parry (Head of Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 20/01/21, shares in Arix Bioscience are trading at 196p, giving the company a market capitalisation of £266.5m. This share price information is delayed by 15 minutes.
Shares in Arix Bioscience are currently trading at 196p and the price has moved by 0.105k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arix Bioscience price has moved by 0.128k% over the past year.
Of the analysts with advisory recommendations for Arix Bioscience, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arix Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arix Bioscience is scheduled to issue upcoming financial results on the following dates:
Arix Bioscience does not currently pay a dividend.
Arix Bioscience does not currently pay a dividend.
Arix Bioscience does not currently pay a dividend.
To buy shares in Arix Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arix Bioscience are currently trading at 196p, giving the company a market capitalisation of £266.5m.
Here are the trading details for Arix Bioscience:
Based on an overall assessment of its quality, value and momentum, Arix Bioscience is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Arix Bioscience are currently priced at 196p. At that level they are trading at 18.92% discount to the analyst consensus target price of 241.74.
Analysts covering Arix Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -0.02265 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arix Bioscience. Over the past six months, the relative strength of its shares against the market has been 0.103k%. At the current price of 196p, shares in Arix Bioscience are trading at 73.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arix Bioscience PE ratio based on its reported earnings over the past 12 months is 17.43. The shares are currently trading at 196p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arix Bioscience's management team is headed by:
Here are the top five shareholders of Arix Bioscience based on the size of their shareholding:
